• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fractyl Labs touts 1-year data for Revita DMR in T2D patients

September 12, 2017 By Sarah Faulkner

FractylFractyl Laboratories touted data today showing sustained improvement in glycemic parameters after one year following a single treatment with its Revita duodenal mucosal resurfacing system in patients with Type II diabetes.

“This is the first presentation of one-year data on the durability of the Revita DMR procedure in Type II diabetes. The Revita DMR procedure was well tolerated, and no serious adverse events related to the device or procedure were reported through one-year of follow up,” co-founder & CEO Dr. Harith Rajagopalan said in prepared remarks. “Additional data on the durability of this intervention’s effects on liver measures in patients with Type II diabetes will also be presented at AASLD later this year.”

The company’s minimally-invasive procedure is designed to rejuvenate the surface of the duodenum to address insulin resistance.

Data from the Revita-1 study showed that a single DMR procedure resulted in sustained reductions in HbA1c, fasting glucose and markers of insulin resistance after one year.

“While there are an increasing number of pharmacological treatments for Type II diabetes, these have little impact on the natural history of the disease and create a significant treatment burden for the patient,” Dr. David Hopkins, director of the Institute of Diabetes, Endocrinology, and Obesity at King’s Health Partners, added. “These data, showing durable improvements in insulin resistance (HOMA-IR) and glycemic control observed over a year, demonstrate the potential for Revita DMR to impact the mechanisms underlying Type II diabetes through a single same-day procedure indicating considerable potential as an alternative approach to escalating drug treatment.”

Fractyl is also enrolling patients in Europe in its Revita-2 trial, which is designed to evaluate the safety and efficacy of the Revita DMR system in orally-treated Type II diabetes patients, the company reported.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Diabetes, Featured Tagged With: fractyllaboratories

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS